U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Ovarian Endometrioid Adenocarcinoma

MedGen UID:
1668743
•Concept ID:
C4725616
•
Neoplastic Process

Definition

Ovarian endometrioid adenocarcinoma that is resistant to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRefractory Ovarian Endometrioid Adenocarcinoma

Professional guidelines

PubMed

Quality of life in ovarian cancer patients choosing to receive salvage chemotherapy or palliative treatment.
Srisuttayasathien M, Khemapech N
Asian Pac J Cancer Prev 2013;14(12):7669-74. doi: 10.7314/apjcp.2013.14.12.7669. PMID: 24460351
Weekly cisplatin and oral etoposide as treatment for relapsed epithelial ovarian cancer.
Meyer T, Nelstrop AE, Mahmoudi M, Rustin GJ
Ann Oncol 2001 Dec;12(12):1705-9. doi: 10.1023/a:1013558501425. PMID: 11843248

Recent clinical studies

Etiology

A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer.
Holloway RW, Thaker P, Mendivil AA, Ahmad S, Al-Niaimi AN, Barter J, Beck T, Chambers SK, Coleman RL, Crafton SM, Crane E, Ramez E, Ghamande S, Graybill W, Herzog T, Indermaur MD, John VS, Landrum L, Lim PC, Lucci JA, McHale M, Monk BJ, Moore KN, Morris R, O'Malley DM, Reid TJ, Richardson D, Rose PG, Scalici JM, Silasi DA, Tewari K, Wang EW
Int J Gynecol Cancer 2023 Sep 4;33(9):1458-1463. doi: 10.1136/ijgc-2023-004812. PMID: 37666539
A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283.
O'Cearbhaill RE, Miller A, Soslow RA, Lankes HA, DeLair D, Segura S, Chavan S, Zamarin D, DeBernardo R, Moore K, Moroney J, Shahin M, Thaker PH, Wahner-Hendrickson AE, Aghajanian C
Gynecol Oncol 2023 Sep;176:16-24. Epub 2023 Jul 5 doi: 10.1016/j.ygyno.2023.06.021. PMID: 37418832Free PMC Article
Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study.
Lee JM, Nair J, Zimmer A, Lipkowitz S, Annunziata CM, Merino MJ, Swisher EM, Harrell MI, Trepel JB, Lee MJ, Bagheri MH, Botesteanu DA, Steinberg SM, Minasian L, Ekwede I, Kohn EC
Lancet Oncol 2018 Feb;19(2):207-215. Epub 2018 Jan 18 doi: 10.1016/S1470-2045(18)30009-3. PMID: 29361470Free PMC Article
Molecular diagnosis in type I epithelial ovarian cancer.
Sadłecki P, Walentowicz-Sadłecka M, Grabiec M
Ginekol Pol 2017;88(12):692-697. doi: 10.5603/GP.a2017.0123. PMID: 29303228
Quality of life in ovarian cancer patients choosing to receive salvage chemotherapy or palliative treatment.
Srisuttayasathien M, Khemapech N
Asian Pac J Cancer Prev 2013;14(12):7669-74. doi: 10.7314/apjcp.2013.14.12.7669. PMID: 24460351

Diagnosis

Expression of Ferredoxin1 in cisplatin‑resistant ovarian cancer cells confers their resistance against ferroptosis induced by cisplatin.
Takahashi R, Kamizaki K, Yamanaka K, Terai Y, Minami Y
Oncol Rep 2023 Jun;49(6) Epub 2023 May 5 doi: 10.3892/or.2023.8561. PMID: 37144519Free PMC Article
Recurrent urothelial carcinoma-like FGFR3 genomic alterations in malignant Brenner tumors of the ovary.
Lin DI, Killian JK, Venstrom JM, Ramkissoon SH, Ross JS, Elvin JA
Mod Pathol 2021 May;34(5):983-993. Epub 2020 Oct 19 doi: 10.1038/s41379-020-00699-1. PMID: 33077920
Molecular diagnosis in type I epithelial ovarian cancer.
Sadłecki P, Walentowicz-Sadłecka M, Grabiec M
Ginekol Pol 2017;88(12):692-697. doi: 10.5603/GP.a2017.0123. PMID: 29303228
Multicenter phase 2 study of combined gemcitabine and epirubicin as second-line treatment for patients with advanced ovarian cancer.
Murgia V, Sorio R, Griso C, Caffo O, Arcuri C, Ferro A, Caldara A, Scalone S, Arisi E, Galligioni E
Int J Gynecol Cancer 2010 Aug;20(6):953-7. doi: 10.1111/IGC.0b013e3181e4a6c1. PMID: 20683401

Therapy

A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer.
Holloway RW, Thaker P, Mendivil AA, Ahmad S, Al-Niaimi AN, Barter J, Beck T, Chambers SK, Coleman RL, Crafton SM, Crane E, Ramez E, Ghamande S, Graybill W, Herzog T, Indermaur MD, John VS, Landrum L, Lim PC, Lucci JA, McHale M, Monk BJ, Moore KN, Morris R, O'Malley DM, Reid TJ, Richardson D, Rose PG, Scalici JM, Silasi DA, Tewari K, Wang EW
Int J Gynecol Cancer 2023 Sep 4;33(9):1458-1463. doi: 10.1136/ijgc-2023-004812. PMID: 37666539
Loratadine for Paclitaxel-Induced Myalgias and Arthralgias.
Smith C, Hendrickson AW, Grudem M, Klampe C, Deering E, Jatoi A
Am J Hosp Palliat Care 2020 Mar;37(3):235-238. Epub 2019 Jul 17 doi: 10.1177/1049909119864083. PMID: 31315424
The Association and Significance of p53 in Gynecologic Cancers: The Potential of Targeted Therapy.
Nakamura M, Obata T, Daikoku T, Fujiwara H
Int J Mol Sci 2019 Nov 4;20(21) doi: 10.3390/ijms20215482. PMID: 31689961Free PMC Article
Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum-resistant or -refractory epithelial ovarian cancer.
Noonan AM, Bunch KP, Chen JQ, Herrmann MA, Lee JM, Kohn EC, O'Sullivan CC, Jordan E, Houston N, Takebe N, Kinders RJ, Cao L, Peer CJ, Figg WD, Annunziata CM
Cancer 2016 Feb 15;122(4):588-597. Epub 2015 Nov 13 doi: 10.1002/cncr.29783. PMID: 26566079Free PMC Article
Local radiation therapy for localized relapsed or refractory ovarian cancer patients with or without symptoms after chemotherapy.
Fujiwara K, Suzuki S, Yoden E, Ishikawa H, Imajo Y, Kohno I
Int J Gynecol Cancer 2002 May-Jun;12(3):250-6. doi: 10.1046/j.1525-1438.2002.01096.x. PMID: 12060445

Prognosis

A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283.
O'Cearbhaill RE, Miller A, Soslow RA, Lankes HA, DeLair D, Segura S, Chavan S, Zamarin D, DeBernardo R, Moore K, Moroney J, Shahin M, Thaker PH, Wahner-Hendrickson AE, Aghajanian C
Gynecol Oncol 2023 Sep;176:16-24. Epub 2023 Jul 5 doi: 10.1016/j.ygyno.2023.06.021. PMID: 37418832Free PMC Article
Expression of Ferredoxin1 in cisplatin‑resistant ovarian cancer cells confers their resistance against ferroptosis induced by cisplatin.
Takahashi R, Kamizaki K, Yamanaka K, Terai Y, Minami Y
Oncol Rep 2023 Jun;49(6) Epub 2023 May 5 doi: 10.3892/or.2023.8561. PMID: 37144519Free PMC Article
Recurrent urothelial carcinoma-like FGFR3 genomic alterations in malignant Brenner tumors of the ovary.
Lin DI, Killian JK, Venstrom JM, Ramkissoon SH, Ross JS, Elvin JA
Mod Pathol 2021 May;34(5):983-993. Epub 2020 Oct 19 doi: 10.1038/s41379-020-00699-1. PMID: 33077920
The Association and Significance of p53 in Gynecologic Cancers: The Potential of Targeted Therapy.
Nakamura M, Obata T, Daikoku T, Fujiwara H
Int J Mol Sci 2019 Nov 4;20(21) doi: 10.3390/ijms20215482. PMID: 31689961Free PMC Article
Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study.
Lee JM, Nair J, Zimmer A, Lipkowitz S, Annunziata CM, Merino MJ, Swisher EM, Harrell MI, Trepel JB, Lee MJ, Bagheri MH, Botesteanu DA, Steinberg SM, Minasian L, Ekwede I, Kohn EC
Lancet Oncol 2018 Feb;19(2):207-215. Epub 2018 Jan 18 doi: 10.1016/S1470-2045(18)30009-3. PMID: 29361470Free PMC Article

Clinical prediction guides

A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283.
O'Cearbhaill RE, Miller A, Soslow RA, Lankes HA, DeLair D, Segura S, Chavan S, Zamarin D, DeBernardo R, Moore K, Moroney J, Shahin M, Thaker PH, Wahner-Hendrickson AE, Aghajanian C
Gynecol Oncol 2023 Sep;176:16-24. Epub 2023 Jul 5 doi: 10.1016/j.ygyno.2023.06.021. PMID: 37418832Free PMC Article
The Association and Significance of p53 in Gynecologic Cancers: The Potential of Targeted Therapy.
Nakamura M, Obata T, Daikoku T, Fujiwara H
Int J Mol Sci 2019 Nov 4;20(21) doi: 10.3390/ijms20215482. PMID: 31689961Free PMC Article
Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study.
Lee JM, Nair J, Zimmer A, Lipkowitz S, Annunziata CM, Merino MJ, Swisher EM, Harrell MI, Trepel JB, Lee MJ, Bagheri MH, Botesteanu DA, Steinberg SM, Minasian L, Ekwede I, Kohn EC
Lancet Oncol 2018 Feb;19(2):207-215. Epub 2018 Jan 18 doi: 10.1016/S1470-2045(18)30009-3. PMID: 29361470Free PMC Article
A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer.
Posadas EM, Liel MS, Kwitkowski V, Minasian L, Godwin AK, Hussain MM, Espina V, Wood BJ, Steinberg SM, Kohn EC
Cancer 2007 Apr 1;109(7):1323-30. doi: 10.1002/cncr.22545. PMID: 17330838Free PMC Article
Paclitaxel efficacy and tolerability in second-line treatment of refractory and relapsed ovarian cancer patients.
Oliverio G, Canuti D, Tononi A, Scarpellini M, Panzini I, Galli I, Ravaioli A
J Chemother 1999 Aug;11(4):301-5. doi: 10.1179/joc.1999.11.4.301. PMID: 10465133

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...